Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Wednesday, July 26th. Stockholders of record on Friday, September 15th will be given a dividend of $0.52 per share on Thursday, September 28th. This represents a $2.08 annualized dividend and a dividend yield of 2.60%. The ex-dividend date of this dividend is Thursday, September 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings data on Wednesday, July, 26th. The company reported $2.56 earnings per share for the quarter, beating analysts' consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business's quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.08 earnings per share. View Gilead Sciences' Earnings History.

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Gilead Sciences.

27 analysts have issued 12-month price objectives for Gilead Sciences' shares. Their predictions range from $68.00 to $100.00. On average, they anticipate Gilead Sciences' share price to reach $86.23 in the next twelve months. View Analyst Ratings for Gilead Sciences.

Here are some recent quotes from research analysts about Gilead Sciences stock:

• 1. According to Zacks Investment Research, "Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which has dampened of late. We note that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives.  Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU. Shares of the company have outperformed the industry so far in 2017." (9/11/2017)
• 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
• 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
• 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
• 5. Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)

Gilead Sciences saw a increase in short interest in September. As of September 15th, there was short interest totalling 22,499,751 shares, an increase of 21.1% from the August 31st total of 18,577,581 shares. Based on an average trading volume of 11,213,920 shares, the short-interest ratio is currently 2.0 days. Currently, 1.7% of the company's shares are sold short.

Some companies that are related to Gilead Sciences include Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), bluebird bio (BLUE), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE) and Halozyme Therapeutics (HALO).

Gilead Sciences' management team includes the folowing people:

• John C. Martin Ph.D., Executive Chairman of the Board
• John F. Milligan Ph.D., Chief Executive Officer, Director
• Robin L. Washington, Chief Financial Officer, Executive Vice President
• Kevin B. Young, Chief Operating Officer
• Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
• James R. Meyers, Executive Vice President - Worldwide Commercial Operations
• John F. Cogan Jr. Ph.D., Lead Independent Director
• Kelly A. Kramer, Independent Director
• Kevin E. Lofton, Independent Director

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eqis Capital Management Inc. (0.01%), Fulton Bank N.A. (0.00%), Neville Rodie & Shaw Inc. (0.00%), Curbstone Financial Management Corp (0.00%), Osborn Williams & Donohoe LLC (0.00%) and Private Asset Management Inc. (0.00%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc., Bridges Investment Counsel Inc., Osborn Williams & Donohoe LLC, Eqis Capital Management Inc. and Neville Rodie & Shaw Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John Francis Cogan, John W Madigan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Gilead Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp and Fulton Bank N.A.. View Insider Buying and Selling for Gilead Sciences.

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Gilead Sciences stock can currently be purchased for approximately $79.95.